Piramal Pharma Q2 FY27 Revenue Up 28% to ₹2,617 Cr
Piramal Pharma Limited announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2026. Consolidated revenue from operations grew 28% YoY to ₹2,617 Crores in Q2FY27 and 23% YoY to ₹4,887 Crores in H1FY27. EBITDA surged 72% YoY in both periods, reaching ₹385 Crores in Q2FY27 and ₹669 Crores in H1FY27, with EBITDA margins expanding over 350 basis points. The company added 22 new customers and successfully hosted 110 customer audits in H1FY27. Piramal Pharma upgraded its FY27 outlook, now expecting revenue growth of 19% to 20% with meaningfully higher profitability, driven by strong performance across its CDMO, CHG, and Consumer Healthcare businesses.
Key Highlights
- Consolidated revenue grew 28% YoY to ₹2,617 Cr in Q2FY27.
- EBITDA increased 72% YoY to ₹385 Cr in Q2FY27.
- EBITDA margin expanded over 350 basis points.
- Added 22 new customers and hosted 110 customer audits in H1FY27.
- Upgraded FY27 outlook for revenue growth and profitability.
Price Impact
More from PPLPHARMA